ABCL — AbCellera Biologics Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual income statement for AbCellera Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	233	375	485	38	28.8
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	80.8	171	269	275	344
Operating Profit	152	204	217	-237	-315
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	158	219	239	-174	-200
Provision for Income Taxes
Net Income After Taxes	119	153	159	-146	-163
Net Income Before Extraordinary Items
Net Income	119	153	159	-146	-163
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	119	153	159	-146	-163
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.452	0.482	0.504	-0.499	-0.412